Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PENICILLIN V (POTASSIUM)

Form:

4 of 4 products shown

2 general benefit · 2 not a benefit

Other products in the same Health Canada class (J01C) — coverage varies; not interchangeable

  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Piperacillin + tazobactam (Tazocin): not a benefit

PEN V-K · DIN 00642215 · 300mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PEN V-K · DIN 00642215 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.7492 Health Canada: Marketed since 2014-09-05 · brand PEN-VK · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Tablet · route Oral · ingredients PENICILLIN V POTASSIUM 300 MG · company Robinson facility supply, inc. · schedule Prescription
Check this DIN again · Health Canada product record

PEN V-K: Formulary list price $0.1873/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1873 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6421 · Verify on the e-Formulary ↗ (DIN 00642215)

Source record
DIN 00642215: PEN V-K Raw flags: sec3=Y Item: 081216034; group id 29; item number 0061; lccId None; manufacturer id AAP Source form: Tab; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.1873; ministry $0.1873 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00642215 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6421
Interchangeable products
PVF-K 500 · DIN 00248843 · not recorded
Shortage status: resolved shortage (ended 2023-05-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00642215
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Pen V-K · DIN 00642223 · 25mg/mL · oral liquid

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.Discontinued 2024-10-24 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Pen V-K · DIN 00642223 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $1.0700 Health Canada: Cancelled post market since 2024-10-24 · brand APO PEN VK · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Powder for solution · route Oral · ingredients PENICILLIN V POTASSIUM 125 MG/5ML · company Parfum international · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Pen V-K: Formulary list price $0.0535/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0535 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6422 · Verify on the e-Formulary ↗ (DIN 00642223)

Source record
DIN 00642223: Apo-Pen V-K Raw flags: sec3=Y Item: 081216035; group id 29; item number 0060; lccId None; manufacturer id APX Source form: O/L; strength: 25mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0535; ministry $0.0535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00642223 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6422
Interchangeable products
Nadopen-V · DIN 00018635 · not recorded
Shortage status: resolved shortage (ended 2019-03-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00642223
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.

Nadopen-V · DIN 00018635 · 25mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.Discontinued 2006-08-25 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nadopen-V · DIN 00018635 Manufacturer: Nadeau Laboratory Ltd.; listing date 1996-10-01 Daily cost (source): $1.0700 Health Canada: Cancelled post market since 2006-08-25 · brand NADOPEN V 200 · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Powder for solution · route Oral · ingredients PENICILLIN V POTASSIUM 40000 UNIT/ML · company Lioh inc. · schedule Prescription
Check this DIN again · Health Canada product record

Nadopen-V: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1512 · Verify on the e-Formulary ↗ (DIN 00018635)

Source record
DIN 00018635: Nadopen-V Raw flags: notABenefit=Y, sec3=Y Item: 081216035; group id 29; item number 0060; lccId None; manufacturer id NDA Source form: O/L; strength: 25mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00018635 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1512
Interchangeable products
Apo-Pen V-K · DIN 00642223 · $0.0535
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00018635
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.

PVF-K 500 · DIN 00248843 · 300mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-04-21 — choose a marketed DIN from the same-category list.Discontinued 1998-04-21 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-04-21 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-04-21 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PVF-K 500 · DIN 00248843 Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01 Daily cost (source): $0.7492 Health Canada: Cancelled post market since 1998-04-21 · brand PVF K500TAB · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Tablet · route Oral · ingredients PENICILLIN V (PENICILLIN V POTASSIUM) 500000 UNIT/TAB · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

PVF-K 500: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1484 · Verify on the e-Formulary ↗ (DIN 00248843)

Source record
DIN 00248843: PVF-K 500 Raw flags: notABenefit=Y, sec3=Y Item: 081216034; group id 29; item number 0061; lccId None; manufacturer id FRS Source form: Tab; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00248843 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1484
Interchangeable products
PEN V-K · DIN 00642215 · $0.1873
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00248843
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1998-04-21 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, CLOXACILLIN 08:12:16 Penicillins

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: moderately infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFUROXIME AXETIL · General benefit (7), Listed, not a benefit (2) Indications CEFTIN (cefuroxime axetil for oral suspension) is indicated for the treatment of patients with mild to moderately severe infections caused by susceptible strains of the designated organisms in the following diseases: • Upper Respiratory Tract Infections: Pharyngitis and tonsillitis caused by Streptococcus pyogenes. PM: https://pdf.hres.ca/dpd_pm/00081954.PDF; date 2025-10-03; DIN 02212307; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications PEN-VK (Penicillin V Potassium (Phenoxymethylpenicillin Potassium)) is indicated for: • Mild to moderately severe infections caused by penicillin V sensitive microorganisms including streptococcal pharyngitis, staphylococcal infection without bacteremia and pneumococcal infections. Therapy should be guided by bacteriologic sensitivity tests and clinical response. Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with potassium phenoxymethyl penicillin during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of potassium phenoxymethyl penicillin: • Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Note: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. • Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. • Staphylococcal infections sensitive to penicillin V: Mild infections of the… https://pdf.hres.ca/dpd_pm/00081311.PDF PM date: August 1, 2025 Source product: PEN-VK; DIN 00642215; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Nadopen-V, PVF-K 500: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026